Literature DB >> 8573157

Molecular cloning of murine CC CKR-4 and high affinity binding of chemokines to murine and human CC CKR-4.

A Hoogewerf1, D Black, A E Proudfoot, T N Wells, C A Power.   

Abstract

We have cloned the murine homologue of human CC Chemokine Receptor-4 (CC CKR-4). In equilibrium competition binding assays performed in undifferentiated HL-60 cells transfected with human and murine CC CKR-4 cDNA, the IC50 values for the binding of [125I]macrophage inflammatory protein-1 alpha to human and murine CC CKR-4 were 14.5 +/- 9.0 nM and 10.1 +/- 3.0 nM, respectively, and the IC50 values for the binding of [125I]RANTES to human and murine CC CKR-4 were 9.3 +/- 3.0 nM and 5.7 +/- 2.6 nM, respectively. The cDNA clone for murine CC CKR-4 is 1531 bp, and the largest open reading frame encodes a protein of 360 amino acids that is 85% identical to human CC CKR-4. Murine CC CKR-4 was detected in the thymus and T-cell lines by Northern blot analysis. This first report of direct binding of chemokines to CC CKR-4 demonstrates that the highly homologous human and murine receptors have similar binding characteristics and tissue distribution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573157     DOI: 10.1006/bbrc.1996.0059

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  CCR4-bearing T cells participate in autoimmune diabetes.

Authors:  Soon H Kim; Mary M Cleary; Howard S Fox; David Chantry; Nora Sarvetnick
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Murine astrocytes express a functional chemokine receptor.

Authors:  S Tanabe; M Heesen; M A Berman; M B Fischer; I Yoshizawa; Y Luo; M E Dorf
Journal:  J Neurosci       Date:  1997-09-01       Impact factor: 6.167

4.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.

Authors:  M Loetscher; B Gerber; P Loetscher; S A Jones; L Piali; I Clark-Lewis; M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

5.  Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.

Authors:  H Heath; S Qin; P Rao; L Wu; G LaRosa; N Kassam; P D Ponath; C R Mackay
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

6.  A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock.

Authors:  Y Chvatchko; A J Hoogewerf; A Meyer; S Alouani; P Juillard; R Buser; F Conquet; A E Proudfoot; T N Wells; C A Power
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

7.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes.

Authors:  P Loetscher; M Seitz; M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

Review 8.  The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.

Authors:  Stefanie Scheu; Shafaqat Ali; Christina Ruland; Volker Arolt; Judith Alferink
Journal:  Int J Mol Sci       Date:  2017-11-02       Impact factor: 5.923

9.  Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.

Authors:  K E Cole; C A Strick; T J Paradis; K T Ogborne; M Loetscher; R P Gladue; W Lin; J G Boyd; B Moser; D E Wood; B G Sahagan; K Neote
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

10.  A distinct chemokine axis does not account for enrichment of Foxp3(+)  CD4(+) T cells in carcinogen-induced fibrosarcomas.

Authors:  Beatrice Ondondo; Emily Colbeck; Emma Jones; Kathryn Smart; Sarah N Lauder; James Hindley; Andrew Godkin; Bernhard Moser; Ann Ager; Awen Gallimore
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.